title: More thoughts on the reporting of adverse events in cancer clinical trials.
authors.forename: Martine
authors.initials: M
authors.lastname: Extermann
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001772:Blood Cell Count; D017322:Clinical Trials, Phase II as Topic; D006801:Humans
chemical_list: D000970:Antineoplastic Agents